Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLF(HA)iri vs FOLFIRI in Metastatic Colorectal Cancer
NCT01290783Phase 3Unknown
- Sponsor
- Alchemia Oncology
- Start
- Dec 2011
- Primary completion
- Oct 2014
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of HyCAMP in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Alchemia Oncology. Primary endpoint: Progression Free Survival at 20 months. Status: unknown.
02
Drugs
HyCAMP
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01290783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01290783.